"It's rare to find drugs in development with excellent safety and efficacy to treat life-threatening infections in children and adults. It's equally rare to find a management team with the experience, accomplishments and expertise necessary to progress those drugs through FDA approval and into clinical practice. In Chimerix, we found both. I am pleased to join a fine group of investors and board directors in support of those efforts," said Dr. Niedel.
"We are pleased to support Chimerix's important product development programs," said Mr. Pappas. "We look forward in particular to meaningful clinical results from CMX001 during 2011 and 2012."
"Chimerix has established a cutting-edge portfolio of novel antiviral medicines with the potential to transform the treatment of certain viruses and address critically-ill patients for whom there would otherwise be little or no hope. We are delighted that such an outstanding group of new investors has joined us in supporting Chimerix in the development of these compounds," said Seth Rudnick, M.D, Venture Partner, Canaan Partners, on behalf of the Chimerix Board.
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.
The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a grow
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved